Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.68−0.11 (-6.15%)
Close on Nov 13, 2026Market cap $2.74MP/E –Yield –
Ernexa Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ernexa Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$14.78M. For fiscal 2025 it was -$9.32M. The highest annual figure on record is $203.00K in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.32M | – |
| FY2024 | Dec 31, 2024 | -$15.67M | – |
| FY2023 | Dec 31, 2023 | -$21.14M | – |
| FY2022 | Dec 31, 2022 | -$33.22M | – |
| FY2021 | Dec 31, 2021 | -$113.73M | – |
| FY2020 | Dec 31, 2020 | -$7.25M | – |
| FY2019 | Dec 31, 2019 | -$1.76M | -968.0% |
| FY2018 | Dec 31, 2018 | $203.00K | – |
| FY2017 | Dec 31, 2017 | -$1.40M | – |
| FY2016 | Dec 31, 2016 | -$2.28M | – |
| FY2015 | Dec 31, 2015 | -$6.90M | – |
| FY2014 | Dec 31, 2014 | -$4.74M | – |
| FY2013 | Dec 31, 2013 | -$1.12M | – |
| FY2012 | Dec 31, 2012 | -$1.06M | – |
| FY2011 | Dec 31, 2011 | -$3.28M | – |
| FY2010 | Dec 31, 2010 | -$325.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.99M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.74M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.52M | – |
| Q3 FY2021 | Sep 30, 2021 | -$86.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.92M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.23M | -809.2% |
| Q3 FY2019 | Sep 30, 2019 | -$316.00K | -185.4% |
| Q2 FY2019 | Jun 30, 2019 | -$2.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$217.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $173.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $370.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$27.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$313.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$489.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$53.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$834.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$300.00K | – |
See a number that looks wrong?